This analysis examines the historical and forecast performance for Merck-Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope
Highlights of this title
Key reasons to purchase this title
- Benchmark Merck-Seronos performance against key rivals in the ethical pharmaceutical sector
- Learn how, led by Rebif and Erbitux, Merck-Serono is set to record strong growth relative to its peer set in the period to 2012
- Evaluate the prospects of Merck-Seronos late-stage pipeline, which is heavily dependent on the oral MS drug Mylinax
